Shire PLC (SHP.L)
* Momenta Pharmaceuticals to regain global development and commercialization rights to M923, a proposed biosimilar of HUMIRA (adalimumab), through termination of collaboration agreement with Baxalta, now part of Shire
* Says has regained from shire plc all development and commercial rights previously licensed for chs-0214 etanercept
* That its wholly owned subsidiary priced its inaugural public offering of $12.1 bln aggregate principal amount of senior notes Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)
* Priced its inaugural public offering of $12.1 billion aggregate principal amount of senior notes
* Court ruled that Cadilla Healthcare Ltd./Zydus Pharmaceuticals (USA) Inc.'s proposed generic version of Lialda does not infringe U.S. patent no. 6,773,720
Shire Plc said the United States Food and Drug Administration (FDA) approved its treatment for patients with primary immunodeficiency, a group of genetic disorders in which part of the body's immune system is missing or functions improperly.
Sept 14 Shire Plc said the United States Food and Drug Administration (FDA) approved its treatment for patients with primary immunodeficiency, a group of genetic disorders in which part of the body's immune system is missing or functions improperly.
* Shire announces U.S. FDA approval of cuvitrutm [immune globulin subcutaneous (human), 20% solution] treatment for primary immunodeficiency
* Announced U.S. launch of Vonvendi [von willebrand factor (recombinant)], only recombinant treatment for adults living with Von Willebrand Disease Source text for Eikon: Further company coverage:
Aug 5 AbbVie Inc said hedge fund Elliott Associates LP has sued the pharmaceuticals company alleging that it had made misrepresentations and omissions related to a failed attempt to buy Dublin-based Shire Plc .
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (SHPG). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : Thomson Reuters Stock Report
"The Economy Matters" Report for SHPGF: the economy's impact on SHPGF's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider : MacroRisk Analytics/EconomicInvestor
Provider : Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.